Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
beer (29) 29
biochemistry (29) 29
chemistry (29) 29
compositions or test papers therefor (29) 29
condition-responsive control in microbiological orenzymological processes (29) 29
enzymology (29) 29
measuring or testing processes involving enzymes, nucleicacids or microorganisms (29) 29
metallurgy (29) 29
microbiology (29) 29
mutation or genetic engineering (29) 29
organic chemistry (29) 29
processes of preparing such compositions (29) 29
spirits (29) 29
vinegar (29) 29
wine (29) 29
oncology (28) 28
female (26) 26
male (26) 26
middle aged (26) 26
aged (23) 23
adult (21) 21
aged, 80 and over (17) 17
colorectal neoplasms - drug therapy (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
compositions thereof (15) 15
culture media (15) 15
derivatives thereof (15) 15
heterocyclic compounds (15) 15
human necessities (15) 15
hygiene (15) 15
index medicus (15) 15
medical or veterinary science (15) 15
microorganisms or enzymes (15) 15
nucleic acids (15) 15
nucleosides (15) 15
nucleotides (15) 15
preparations for medical, dental, or toilet purposes (15) 15
propagating, preserving or maintaining microorganisms (15) 15
specific therapeutic activity of chemical compounds ormedicinal preparations (15) 15
sugars (15) 15
chemotherapy (13) 13
colorectal neoplasms - genetics (13) 13
colorectal cancer (11) 11
treatment outcome (11) 11
fluorouracil - administration & dosage (10) 10
polymorphism, genetic (10) 10
cancer (9) 9
survival rate (9) 9
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (8) 8
fluorouracil - therapeutic use (8) 8
leucovorin (8) 8
organoplatinum compounds - administration & dosage (8) 8
oxaliplatin (8) 8
retrospective studies (8) 8
antineoplastic agents - therapeutic use (7) 7
colorectal neoplasms - pathology (7) 7
fluorouracil (7) 7
genotype (7) 7
hematology, oncology and palliative medicine (7) 7
leucovorin - administration & dosage (7) 7
messenger-rna levels (7) 7
peptides (7) 7
polymorphism (7) 7
polymorphism, restriction fragment length (7) 7
prognosis (7) 7
thymidylate synthase - genetics (7) 7
tumors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cisplatin (6) 6
colorectal neoplasms - enzymology (6) 6
expression (6) 6
gene expression regulation, neoplastic (6) 6
pharmacogenetics (6) 6
single nucleotide polymorphism (6) 6
survival (6) 6
survival analysis (6) 6
adenocarcinoma - drug therapy (5) 5
animals (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
biomarkers, tumor - genetics (5) 5
cancer therapies (5) 5
cisplatin - administration & dosage (5) 5
colorectal neoplasms - mortality (5) 5
dna primers (5) 5
follow-up studies (5) 5
organoplatinum compounds - therapeutic use (5) 5
polymerase chain reaction (5) 5
risk factors (5) 5
stomach neoplasms - drug therapy (5) 5
thymidylate-synthase gene (5) 5
5-fluorouracil (4) 4
base sequence (4) 4
cancer patients (4) 4
care and treatment (4) 4
cetuximab (4) 4
colorectal-cancer (4) 4
disease-free survival (4) 4
dna repair (4) 4
dna-binding proteins (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
by Folprecht, Gunnar, Dr and Gruenberger, Thomas, Prof and Bechstein, Wolf O, Prof and Raab, Hans-Rudolf, Prof and Lordick, Florian, MD and Hartmann, Jörg T, Prof and Lang, Hauke, Prof and Frilling, Andrea, Prof and Stoehlmacher, Jan, MD and Weitz, Jürgen, MD and Konopke, Ralf, MD and Stroszczynski, Christian, Prof and Liersch, Torsten, MD and Ockert, Detlev, Prof and Herrmann, Thomas, Prof and Goekkurt, Eray, MD and Parisi, Fabio, PhD and Köhne, Claus-Henning, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
by Hegewisch-Becker, Susanna, Prof and Graeven, Ullrich, MD and Lerchenmüller, Christian A, MD and Killing, Birgitta, MD and Depenbusch, Reinhard, MD and Steffens, Claus-Christoph, MD and Al-Batran, Salah-Eddin, Prof and Lange, Thoralf, Prof and Dietrich, Georg, MD and Stoehlmacher, Jan, Prof and Tannapfel, Andrea, Prof and Reinacher-Schick, Anke, Prof and Quidde, Julia, MD and Trarbach, Tanja, MD and Hinke, Axel, PhD and Schmoll, Hans-Joachim, Prof and Arnold, Dirk, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Summary Background The definition of a best maintenance strategy following combination chemotherapy plus bevacizumab in metastatic colorectal cancer is... 
Hematology, Oncology and Palliative Medicine | CAPECITABINE | THERAPY | ONCOLOGY | COMBINATION | STOP | CHEMOTHERAPY | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Leucovorin - therapeutic use | Maintenance Chemotherapy | Angiogenesis Inhibitors - adverse effects | Colorectal Neoplasms - mortality | Risk Factors | Kaplan-Meier Estimate | Capecitabine - therapeutic use | Disease Progression | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Colorectal Neoplasms - pathology | Drug Substitution | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Colorectal cancer | Product development | Metastasis | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
by Salah-Eddin Al-Batran and Joerg Thomas Hartmann and Stephan Probst and Harald Schmalenberg and Stephan Hollerbach and Ralf Hofheinz and Volker Rethwisch and Gernot Seipelt and Nils Homann and Gerhard Wilhelm and Gunter Schuch and Jan Stoehlmacher and Hans Günter Derigs and Susanna Hegewisch-Becker and Johannes Grossmann and Claudia Pauligk and Akin Atmaca and Carsten Bokemeyer and Alexander Knuth and Elke Jäger and Arbeitsgemeinschaft Internistische Onkologie
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1435 - 1442
Purpose This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced... 
1ST-LINE TREATMENT | 5-FLUOROURACIL | INFUSIONAL FLUOROURACIL | THERAPY | ONCOLOGY | EUROPEAN ORGANIZATION | ADVANCED GASTRIC-CANCER | FOLINIC ACID | ELDERLY-PATIENTS | FOLFOX-4 | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
by Al-Batran, Salah-Eddin and Homann, Nils and Pauligk, Claudia and Goetze, Thorsten O and Meiler, Johannes and Kasper, Stefan and Kopp, Hans-Georg and Mayer, Frank and Haag, Georg Martin and Luley, Kim and Lindig, Udo and Schmiegel, Wolff and Pohl, Michael and Stoehlmacher, Jan and Folprecht, Gunnar and Probst, Stephan and Prasnikar, Nicole and Fischbach, Wolfgang and Mahlberg, Rolf and Trojan, Jörg and Koenigsmann, Michael and Martens, Uwe M and Thuss-Patience, Peter and Egger, Matthias and Block, Andreas and Heinemann, Volker and Illerhaus, Gerald and Moehler, Markus and Schenk, Michael and Kullmann, Frank and Behringer, Dirk M and Heike, Michael and Pink, Daniel and Teschendorf, Christian and Löhr, Carmen and Bernhard, Helga and Schuch, Gunter and Rethwisch, Volker and von Weikersthal, Ludwig Fischer and Hartmann, Jörg T and Kneba, Michael and Daum, Severin and Schulmann, Karsten and Weniger, Jörg and Belle, Sebastian and Gaiser, Timo and Oduncu, Fuat S and Güntner, Martina and Hozaeel, Wael and Reichart, Alexander and Jäger, Elke and Kraus, Thomas and Mönig, Stefan and Bechstein, Wolf O and Schuler, Martin and Schmalenberg, Harald and Hofheinz, Ralf D and FLOT4-AIO Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
by Folprecht, Gunnar and Hamann, Susanne and Schütte, Katharina and Trarbach, Tanja and Stoehlmacher-Williams, Jan and Ehninger, Gerhard
BMC Cancer, ISSN 1471-2407, 07/2014, Volume 14, Issue 1, pp. 521 - 521
Background: The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival... 
Irinotecan | Chemotherapy | Oxaliplatin | Phase I | Cetuximab | Metastatic colorectal cancer | 5-FU | 1ST-LINE TREATMENT | LEUCOVORIN | FOLFIRINOX | GUIDELINES | FLUOROURACIL | PHASE-III TRIAL | LIVER METASTASES | ONCOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Maximum Tolerated Dose | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Liver Neoplasms - secondary | Organoplatinum Compounds - adverse effects | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
by Eray Goekkurt and Salah-Eddin Al-Batran and Jörg T. Hartmann and Ulrike Mogck and Gunter Schuch and Michael Kramer and Elke Jaeger and Carsten Bokemeyer and Gerhard Ehninger and Jan Stoehlmacher
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 17, pp. 2863 - 2873
Purpose To evaluate the association of germ-line polymorphisms of genes that may impact treatment outcome of platinum and fluorouracil combination chemotherapy... 
THYMIDYLATE-SYNTHASE GENE | TANDEM REPEAT POLYMORPHISM | COLORECTAL-CANCER PATIENTS | METHIONINE-SYNTHASE | ONCOLOGY | ADVANCED GASTRIC-CANCER | SQUAMOUS-CELL CARCINOMA | SINGLE NUCLEOTIDE POLYMORPHISM | ACUTE MYELOID-LEUKEMIA | MESSENGER-RNA LEVELS | S-TRANSFERASE-PI | Stomach Neoplasms - genetics | Pharmacogenetics - methods | Humans | Middle Aged | Male | Clinical Trials as Topic | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Adenocarcinoma - genetics | Aged | Organoplatinum Compounds - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma
by Hoffmann, Andreas-Claudius and Goekkurt, Eray and Danenberg, Peter V and Lehmann, Sylvia and Ehninger, Gerhard and Aust, Daniela E and Stoehlmacher-Williams, Jan
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e64186
Background: Cholangiocarcinoma remains to be a tumor with very few treatment choices and limited prognosis. In this study, we sought to determine the... 
LUNG-CANCER | CELLS | VEGF | MULTIDISCIPLINARY SCIENCES | PDGFA | HIGH EXPRESSION | BFGF | PANCREATIC DUCTAL ADENOCARCINOMAS | HIF1A | CHEMOTHERAPY | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Glucuronidase - metabolism | Male | Bile Duct Neoplasms - enzymology | Receptor, Epidermal Growth Factor - metabolism | Statistics, Nonparametric | Aged, 80 and over | Biomarkers, Tumor - metabolism | Female | Bile Duct Neoplasms - genetics | Cholangiocarcinoma - enzymology | Vascular Endothelial Growth Factor Receptor-1 - genetics | Bile Ducts, Intrahepatic - pathology | Risk Factors | Kaplan-Meier Estimate | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Bile Ducts, Intrahepatic - enzymology | Cholangiocarcinoma - pathology | Glucuronidase - genetics | Survival Analysis | Cholangiocarcinoma - genetics | ROC Curve | Aged | Biomarkers, Tumor - genetics | Bile Duct Neoplasms - pathology | Tyrosine | Messenger RNA | Genes | Muscle proteins | Gene expression | Growth factors | Formaldehyde | Platelet-derived growth factor | Lung cancer | Oncology | Risk | Metastasis | Paraffin | Kinases | Tissues | Medical diagnosis | Cancer therapies | Subgroups | Epidermal growth factor | Actin | Vascular endothelial growth factor | Protein-tyrosine kinase | Cholangiocarcinoma | Medical research | Lymphatic system | Polypeptides | Internal medicine | Epidermal growth factor receptors | Markers | Regression analysis | Patients | Survival | Polymerase chain reaction | Medicine | Chemotherapy | Hospitals | Hypoxia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
by Yoshinori Shirota and Jan Stoehlmacher and Jan Brabender and Yi-Ping Xiong and Hiroyuki Uetake and Kathleen D. Danenberg and Susan Groshen and Denise D. Tsao-Wei and Peter V. Danenberg and Heinz-Josef Lenz
Journal of Clinical Oncology, ISSN 0732-183X, 12/2001, Volume 19, Issue 23, pp. 4298 - 4304
Purpose: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene... 
YEAST | DNA MISMATCH REPAIR | 5-FLUOROURACIL | CISPLATIN | ONCOLOGY | ADENOCARCINOMA | EXPRESSION LEVELS | RESISTANCE | MESSENGER-RNA LEVELS | NUCLEOTIDE EXCISION-REPAIR | CHI-SQUARE STATISTICS | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | RNA, Messenger - metabolism | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | DNA-Binding Proteins | Colorectal Neoplasms - mortality | Thymidylate Synthase - metabolism | California | DNA Primers | Reverse Transcriptase Polymerase Chain Reaction | Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endonucleases | Survival Analysis | Aged | Colorectal Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Prediction of efficacy and side effects of chemotherapy in colorectal cancer
by Stoehlmacher, Jan
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, ISSN 0080-0015, 2007, Volume 176, pp. 81 - 88
Treatment of gastrointestinal cancers has significantly advanced over the last several years with the introduction of effective chemotherapeutic and targeted... 
Antineoplastic Agents - metabolism | Prognosis | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Enzymes - genetics | Humans | Treatment Outcome | Polymorphism, Genetic
Journal Article
Details down arrow
10. Full Text EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma
by Hoffmann, Andreas-Claudius and Gökkurt, Eray and Danenberg, Peter V and Lehmann, Sylvia and Ehninger, Gerhard and Aust, Daniela E and Stoehlmacher, Jan
ISSN 1932-6203, 2013
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Detection and Monitoring of Cell-Free DNA in Blood of Patients with Colorectal Cancer
by Schwarzenbach, Heidi and Stoehlmacher, Jan and Pantel, Klaus and Goekkurt, Eray
Annals of the New York Academy of Sciences, ISSN 0077-8923, 08/2008, Volume 1137, Issue 1, pp. 190 - 196
Cell-free tumor-specific and normal DNA are released into the blood circulation by cellular necrosis and apoptosis. We examined whether circulating DNA in... 
serum DNA concentrations | colon cancer | circulating DNA | Serum DNA concentrations | Circulating DNA | Colon cancer | BIOCHEMISTRY & MOLECULAR BIOLOGY | MULTIDISCIPLINARY SCIENCES | PLASMA DNA | TUMORS | Colorectal Neoplasms - blood | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | DNA - blood | Biomarkers, Tumor - blood | Disease-Free Survival | DNA, Neoplasm - blood | Aged, 80 and over | Adult | Female | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Genetic research | Cancer patients | Genetic aspects | DNA | Colorectal cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
by Al-Batran, Salah-Eddin and Pauligk, Claudia and Homann, Nils and Hartmann, Jörg T and Moehler, Markus and Probst, Stephan and Rethwisch, Volker and Stoehlmacher-Williams, Jan and Prasnikar, Nicole and Hollerbach, Stephan and Bokemeyer, Carsten and Mahlberg, Rolf and Hofheinz, Ralf D and Luley, Kim and Kullmann, Frank and Jäger, Elke
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 49, Issue 4, pp. 835 - 842
Abstract Background We evaluated the feasibility and tolerability of triple- versus double-drug chemotherapy in elderly patients with oesophagogastric cancer.... 
Hematology, Oncology and Palliative Medicine | Oesophageal cancer | Chemotherapy | Gastric cancer | Elderly | LEUCOVORIN | OXALIPLATIN | METASTATIC ADENOCARCINOMA | FLUOROURACIL | DOCETAXEL | JUNCTION | PHASE-II TRIAL | CISPLATIN | ONCOLOGY | ADVANCED GASTRIC-CANCER | POOLED ANALYSIS | Leucovorin - administration & dosage | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophageal Neoplasms - pathology | Feasibility Studies | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Female | Aged | Neoplasm Staging | Esophageal Neoplasms - drug therapy | Aged patients | Cancer patients | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity
by Mandola, Michael V and Stoehlmacher, Jan and Muller-Weeks, Susan and Cesarone, Gregory and Yu, Mimi C and Lenz, Heinz-Josef and Ladner, Robert D
Cancer Research, ISSN 0008-5472, 06/2003, Volume 63, Issue 11, pp. 2898 - 2904
Thymidylate synthase (TS) gene expression is modulated by a polymorphism in the 5' regulatory region of the gene. The polymorphism consists mainly of either... 
MESSENGER-RNA | CANCER-CHEMOTHERAPY | ONCOLOGY | UPSTREAM | COLORECTAL-CANCER | DNA | ENHANCER REGION | THYMINELESS DEATH | REGULATORY REGION | REPEATED SEQUENCES | PROMOTER | Humans | Regulatory Sequences, Nucleic Acid | Transcriptional Activation | Molecular Sequence Data | Transcription Factors - antagonists & inhibitors | Transcription Factors - genetics | Thymidylate Synthase - genetics | Upstream Stimulatory Factors | E-Box Elements | Luciferases - genetics | Transcription Factors - metabolism | Ethnic Groups - genetics | Polymorphism, Restriction Fragment Length | Base Sequence | Polymorphism, Single Nucleotide - genetics | Binding Sites | Tandem Repeat Sequences - genetics | Genes, Reporter | DNA-Binding Proteins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Association of high microsatellite instability (MSI-H) with a high immunoscore (IS) compared to PD-L1 expression and increased survival in patients (pts) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (Ox) and fluoropyrimidine (FP): A pooled analysis of the AIO KRK 0207 and RO91 trials
by Noepel-Duennebacke, Stefanie and Juette, Hendrik and Schulmann, Karsten and Graeven, Ullrich and Porschen, Rainer and Stoehlmacher, Jan and Hegewisch-Becker, Susanna and Mosig, Axel and Arnold, Dirk and Reinacher-Schick, Anke C and Tannapfel, Andrea
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 3595 - 3595
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation
by Stoehlmacher, Jan and Goekkurt, Eray and Mogck, Ulrike and Aust, Daniela E and Kramer, Michael and Baretton, Gustavo B and Liersch, Torsten and Ehninger, Gerhard and Jakob, Christiane
Cancer Letters, ISSN 0304-3835, 2008, Volume 272, Issue 2, pp. 221 - 225
Abstract Purpose According to the CAO-/ARO-/AIO-94 trial of the German Rectal Cancer Study Group, pre-operative 5-fluorouracil (5-FU)-based long-term... 
Hematology, Oncology and Palliative Medicine | TS polymorphism | Rectal Cancer | LEUCOVORIN | DIHYDROPYRIMIDINE DEHYDROGENASE | CHEMORADIOTHERAPY | CHEMOTHERAPY | GENE | ONCOLOGY | COLORECTAL-CANCER | SINGLE NUCLEOTIDE POLYMORPHISM | EXPRESSION | THYMIDINE PHOSPHORYLASE | TS | Humans | Middle Aged | RNA, Messenger - genetics | Genotype | Male | Treatment Outcome | Combined Modality Therapy | Thymidylate Synthase - genetics | Rectal Neoplasms - enzymology | Rectal Neoplasms - radiotherapy | Polymorphism, Genetic | Fluorouracil - therapeutic use | Female | Chemotherapy, Adjuvant | Rectal Neoplasms - drug therapy | Cancer patients | Care and treatment | RNA | Analysis | Colorectal cancer | Genetic aspects | Fluorouracil | Tumors | Haplotypes | Colleges & universities | Gene expression | Cancer therapies | DNA repair | Deoxyribonucleic acid--DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer
by Stoehlmacher, Jan and Park, David J and Zhang, Wu and Groshen, Susan and Tsao-Wei, Denice D and Yu, Mimi C and Lenz, Heinz-Josef
Journal of the National Cancer Institute, ISSN 0027-8874, 06/2002, Volume 94, Issue 12, pp. 936 - 942
Background: Members of the glutathione S-transferase (GST) superfamily are important in cellular defense mechanisms. These enzymes attach reduced glutathione... 
BREAST-CANCER | RESISTANT | CISPLATIN | ONCOLOGY | HUMAN-TISSUES | SUSCEPTIBILITY | PI | EXPRESSION | CELL-LINE | NECK-CANCER | CHEMOTHERAPY | Follow-Up Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Ethnic Groups - genetics | Glutathione Transferase - genetics | Oxaliplatin | Time Factors | Base Sequence | Aged, 80 and over | Adult | Female | Retrospective Studies | Colorectal Neoplasms - mortality | Colorectal Neoplasms - enzymology | Isoenzymes - genetics | California | Continental Population Groups - genetics | DNA Primers | Polymorphism, Restriction Fragment Length | Survival Analysis | Aged | Glutathione S-Transferase pi | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Amino Acid Substitution | Glutathione transferase | Patient outcomes | Colorectal cancer | Physiological aspects | Genetic aspects | Health aspects | Cancer | Fluorouracil
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights